// App-Quantinova.ai

AB0538 (2021) : POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR

Researchers

Presenter

  • C. T. Ritchlin

Principal Investigators

  • P. Rahman

  • P. Helliwell

  • W. H. Boehncke

  • I. Mcinnes

  • A. B. Gottlieb

  • S. Kafka

  • A. Kollmeier

  • E. C. Hsia

  • X. L. Xu

  • M. Shawi

  • S. Sheng

  • P. Agarwal

  • B. Zhou

  • P. Ramachandran

  • P. J. Mease

Medical Centers

  • University of Rochester, School of Medicine and Dentistry, Rochester, United States of America

  • Memorial University of Newfoundland, Disicpline of Medicine, Faculty of Medicine, St. Johns, Canada

  • University of Leeds, Rheumatology, Leeds, United Kingdom

  • University of Glasgow, Director of Dermatology, Glasgow, United Kingdom

  • Icahn School of Medicine Mt. Sinai, Dermatology, New York, United States of America

  • Janssen Scientific Affairs, MED GROUP RHEUM TA, Horsham, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • University of Pennsylvania School of Medicine, Immunology, Philadelphia, United States of America

  • Janssen Scientific Affairs, GMA COMMERCIAL OPS, Horsham, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Rheumatology Research, Seattle, United States of America

Locations

  • United States

  • Canada

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved